About Exeltis
Exeltis is an organization committed to innovation, excellence and healthcare. Our aim is to become a point of reference in the pharmaceutical sector.
About us
A step forward in improving health
Exeltis is the result of the natural evolution and sustained growth of the CHEMO pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide.
Human wellbeing and health: our driving force
People are our core concern and guiding force. In order to provide better therapeutic solutions and reach more people worldwide, Exeltis has taken its operations to every continent, giving even more patients rapid and effective access to our wide range of products.
Entrepreneurial organization in constant evolution
With our innovative spirit, we use all our know-how, resources and human capital to develop solutions that meet patients’ unsatisfied needs. Our endeavour to find new therapeutic alternatives had led us to join forces with other leading pharmaceutical companies that share our enthusiasm and to establish alliances in order to progress together in healthcare.
Our main mission is twofold:
What defines us
“Exeltis is an exaltation of excellence, innovation and diversity”
Our philosophy, character and work ethos are captured in our emblem “Rethinking Healthcare”
- Entrepreneurial and innovative spirit.
- Maverick, forward-looking organization.
- Sustained growth focussed on improving human health.
- Global vision and local action.
- Innovation combined with knowledge and experience.
- Organization in constant evolution and motion.
- Our team: specialist, flexible, creative, enthusiastic and motivate.
Key facts
- Global organization, with presence in over 40 countries.
- Close to 4,000 professionals devote to improve human health.
- Strong position in the Women’s Health sector and other areas such as Respiratory, Dermatology and Ophthalmology.
- Portfolio of more than 300 medicines and products accessible to millions of people.
- Solid commercial structure with about 2,000 medical representatives.
- Innovative, rapidly expanding and evolving organisation with over 30 subsidiaries worldwide.
- Excellence, diversity and integrity in its activity.
- Global manufacturing network in Europe, The Americas and Asia.
Milestones
2003
The CHEMO Group start up branded pharmaceutical business in Europe after acquiring 50% of EFFIK, a specialist company in gynaecology.
2005
2007
2007
Strategic alliances open the door to Asia through Sinensix Pharma (Tailand, Vietnam), to Russia and CIS countries with the new BC Pharma subsidiary and to Mexico thanks to Elea Mexico.
2008
Growth continues in Asia with Chemo Wanbang Biopharma and Chemway.
Agreement to market a novel, unique treatment for diabetic foot.
2009
2010
2010
The company increases its production capacity in America by joining the US market through Everett Labs and the new group members, Altian Pharma (Central America), VyT Pharma (Paraguay), Everett (USA).
Its presence in Europe expands to the largest market, Germany, through Velvian, as well as to Poland and Eastern Europe, where it was already present with TemaPharm y Ladee Pharma, respectively.
2012
Consolidation of South-East Asian market with Nufarindo (Indonesia) and Exeltis Malaysia, start of operations in India with a new partner, Ordain, and the addition of Austria and Switzerland to the European market with Velvian and Veldana, respectively. Its American operations are strengthened with Eticos (Paraguay).
Creation of the Ladee Pharma Research Institute (LPRI), engaged in developing new products, primarily in the Women's Health sector.
2013
The company arrives in Africa with the acquisition of Althéa Pharma, specifically in the Moroccan market, with special emphasis on Women's Health, in which we are a company of reference.
Evolution and sustained growth in the branded pharmaceuticals market leads to the creation of Exeltis.
Exeltis consolidates its presence in the United States. It has acquired 100% of Quinnova Pharmaceuticals, a US company specializing in a wide variety of dermatological products.
2014
Exeltis has acquired 100% of the Turkish pharmaceutical Embil. The deal is the biggest acquisition ever by Exeltis abroad. The deal is part of Exeltis's Strategic Plan that aims to consolidate its international development.
-
2003
-
2005
2007 -
2008
-
2009
2010 -
2012
-
2013
-
2014
Our commitment
“Excellence, respect, responsibility and integrity are our values”
Committed to people’s health and wellbeing
We work hard to meet our commitments on a daily basis. All our efforts, resources and human capital are people-oriented and focussed on developing medicinal products that can help improve human health.
In our endeavour to provide health solutions and make our products more readily and easily accessible, we establish alliances that enable us to operate worldwide.
Accountability
Aware of the significant impact our activities have on people’s quality of life, we do not simply provide medical solutions – we make sure that all our products meet the highest standards of quality and safety.
All our processes are held to strict standards and comply with current international legislation and guidelines, in addition to our own quality and safety policies.
Respect for the environment
We aim to achieve sustainable development, and to do so we carefully assess our environmental footprint and protect and improve our environment.
Exeltis is committed to protecting the environment, and we are constantly improving our processes, products and services to this end. We endeavour to minimise the impact of our production activities, facilities and offices worldwide, to guarantee effective waste management and efficient use of resources and to promote ecological habits throughout the organisational chain.
Committed to the fight against neglected diseases
Through Mundo Sano Foundation, Exeltis works to reduce the impact of Neglected Tropical Diseases (NTDs) such as Chagas disease and Dengue fever by researching, preventing and treating these conditions which affect billions of people worldwide, particularly in developing countries.
Mundo Sano is part of a global alliance, led by the Bill & Melinda Gates Foundation, which aims to promote cooperation for the immediate control or eradication of 10 Neglected Tropical Diseases (NTDs). It supports the objectives established by the World Health Organization (WHO) and the United Nations Millennium Development Goals (MDGs) for 2020.
